• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Activated partial thromboplastin time and risk of future venous thromboembolism.活化部分凝血活酶时间与未来静脉血栓栓塞风险
Am J Med. 2008 Mar;121(3):231-8. doi: 10.1016/j.amjmed.2007.10.025.
2
Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study.峰值凝血酶生成与随后的静脉血栓栓塞:血栓形成病因的纵向研究(LITE 研究)。
J Thromb Haemost. 2009 Oct;7(10):1639-48. doi: 10.1111/j.1538-7836.2009.03561.x. Epub 2009 Jul 28.
3
Haematological variables and risk of future venous thromboembolism in the British Regional Heart Study on men. Combined D-dimer and APTT as a predictive test for thromboembolism?男性英国地区心脏研究中的血液学变量与未来静脉血栓栓塞风险。联合 D-二聚体和 APTT 作为血栓栓塞的预测性试验?
Br J Haematol. 2022 Aug;198(3):587-594. doi: 10.1111/bjh.18288. Epub 2022 Jun 2.
4
A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.活化部分凝血活酶时间缩短与静脉血栓栓塞风险相关。
Blood. 2004 Dec 1;104(12):3631-4. doi: 10.1182/blood-2004-03-1042. Epub 2004 Aug 5.
5
Clinical and Prognostic Significance of Coagulation Assays in Pancreatic Cancer Patients With Absence of Venous Thromboembolism.凝血检测在无静脉血栓栓塞的胰腺癌患者中的临床及预后意义
Am J Clin Oncol. 2015 Dec;38(6):550-6. doi: 10.1097/01.coc.0000436088.69084.22.
6
Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE).凝血因子、炎症标志物与静脉血栓栓塞:血栓栓塞病因纵向研究(LITE)
Am J Med. 2002 Dec 1;113(8):636-42. doi: 10.1016/s0002-9343(02)01345-1.
7
Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19.凝血生物标志物是 COVID-19 患者需氧量增加的独立预测因子。
J Thromb Haemost. 2020 Nov;18(11):2942-2953. doi: 10.1111/jth.15067. Epub 2020 Sep 18.
8
Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology.凝血因子IX至XIII与未来静脉血栓形成风险:血栓栓塞病因纵向研究
Blood. 2009 Oct 1;114(14):2878-83. doi: 10.1182/blood-2009-05-219915. Epub 2009 Jul 17.
9
Elevated activated partial thromboplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism.基于活化部分凝血活酶时间的凝血波形分析标志物升高与急性静脉血栓栓塞症有很强的正相关性。
Biochem Med (Zagreb). 2019 Jun 15;29(2):020710. doi: 10.11613/BM.2019.020710.
10
A shortened activated partial thromboplastin time predicts the risk of catheter-associated venous thrombosis in cancer patients.活化部分凝血活酶时间缩短可预测癌症患者发生导管相关静脉血栓形成的风险。
Thromb Res. 2014 Jul;134(1):165-8. doi: 10.1016/j.thromres.2014.04.022. Epub 2014 Apr 29.

引用本文的文献

1
Genome-wide association and linkage analysis of histidine-rich glycoprotein identifies common variants associated with plasma histidine-rich glycoprotein concentrations.富含组氨酸糖蛋白的全基因组关联和连锁分析确定了与血浆富含组氨酸糖蛋白浓度相关的常见变异。
Res Pract Thromb Haemost. 2025 Jun 24;9(5):102955. doi: 10.1016/j.rpth.2025.102955. eCollection 2025 Jul.
2
Construction and validation of risk prediction models for pulmonary embolism in hospitalized patients based on different machine learning methods.基于不同机器学习方法的住院患者肺栓塞风险预测模型的构建与验证
Front Cardiovasc Med. 2024 Jun 25;11:1308017. doi: 10.3389/fcvm.2024.1308017. eCollection 2024.
3
A nomogram to predict the risk of venous thromboembolism in patients with colon cancer in China.用于预测中国结肠癌患者静脉血栓栓塞风险的列线图。
Cancer Med. 2024 May;13(9):e7231. doi: 10.1002/cam4.7231.
4
Coagulation Status Using Clot Wave Analysis in Patients With Prolonged Immobilization.长时间制动患者凝血状态的血栓波分析
Cureus. 2024 Jan 1;16(1):e51483. doi: 10.7759/cureus.51483. eCollection 2024 Jan.
5
Development and Validation of a Prediction Model for Venous Thrombus Embolism (VTE) in Patients With Colorectal Cancer.开发和验证用于预测结直肠癌患者静脉血栓栓塞症(VTE)的模型。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231186790. doi: 10.1177/15330338231186790.
6
Midlife Hemostasis Measures, 20-Year Cognitive Decline, and Incident Dementia.中年止血措施、20 年认知能力下降与痴呆症发病。
Neurology. 2023 Oct 24;101(17):e1697-e1707. doi: 10.1212/WNL.0000000000207771. Epub 2023 Aug 31.
7
Immune disturbance leads to pulmonary embolism in COVID-19 more than classical risk factors: a clinical and histological study.免疫紊乱导致 COVID-19 肺栓塞甚于经典危险因素:临床与组织学研究。
Intern Emerg Med. 2023 Oct;18(7):1981-1993. doi: 10.1007/s11739-023-03383-9. Epub 2023 Aug 17.
8
Perilla oil and α-linolenic acid ameliorated thrombosis in rats induced by collagen and epinephrine.紫苏油和α-亚麻酸改善了胶原蛋白和肾上腺素诱导的大鼠血栓形成。
Food Sci Biotechnol. 2023 Jan 25;32(7):997-1003. doi: 10.1007/s10068-022-01241-6. eCollection 2023 Jun.
9
Predictors of Symptomatic Venous Thromboembolism in Patients with Soft Tissue Sarcoma in the Lower Extremity.下肢软组织肉瘤患者症状性静脉血栓栓塞的预测因素
Cancers (Basel). 2023 Jan 3;15(1):315. doi: 10.3390/cancers15010315.
10
Haemostasis and Inflammatory Parameters as Potential Diagnostic Biomarkers for VTE in Trauma-Immobilized Patients.止血和炎症参数作为创伤固定患者静脉血栓栓塞症潜在的诊断生物标志物
Diagnostics (Basel). 2023 Jan 2;13(1):150. doi: 10.3390/diagnostics13010150.

本文引用的文献

1
Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time.活化部分凝血活酶时间对复发性静脉血栓栓塞的预测
J Thromb Haemost. 2006 Apr;4(4):752-6. doi: 10.1111/j.1538-7836.2006.01868.x.
2
Obesity as a risk factor in venous thromboembolism.肥胖作为静脉血栓栓塞的一个风险因素。
Am J Med. 2005 Sep;118(9):978-80. doi: 10.1016/j.amjmed.2005.03.012.
3
Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis.家族中FVIII:C水平升高与静脉和动脉血栓形成风险增加相关。
J Thromb Haemost. 2005 Jan;3(1):79-84. doi: 10.1111/j.1538-7836.2004.01033.x.
4
A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.活化部分凝血活酶时间缩短与静脉血栓栓塞风险相关。
Blood. 2004 Dec 1;104(12):3631-4. doi: 10.1182/blood-2004-03-1042. Epub 2004 Aug 5.
5
Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology.两个队列中的深静脉血栓形成和肺栓塞:血栓栓塞病因的纵向研究
Am J Med. 2004 Jul 1;117(1):19-25. doi: 10.1016/j.amjmed.2004.01.018.
6
The partial thromboplastin time: defining an era in coagulation.部分凝血活酶时间:定义凝血领域的一个时代。
J Thromb Haemost. 2003 Nov;1(11):2267-70. doi: 10.1046/j.1538-7836.2003.00459.x.
7
Levels of coagulation factors and venous thromboembolism.凝血因子水平与静脉血栓栓塞症
Haematologica. 2003 Jun;88(6):705-11.
8
Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use.肥胖:静脉血栓形成风险以及与凝血因子水平和口服避孕药使用之间的相互作用。
Thromb Haemost. 2003 Mar;89(3):493-8.
9
Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE).凝血因子、炎症标志物与静脉血栓栓塞:血栓栓塞病因纵向研究(LITE)
Am J Med. 2002 Dec 1;113(8):636-42. doi: 10.1016/s0002-9343(02)01345-1.
10
Fibrin fragment D-dimer and the risk of future venous thrombosis.纤维蛋白片段D-二聚体与未来静脉血栓形成风险
Blood. 2003 Feb 15;101(4):1243-8. doi: 10.1182/blood-2002-05-1416. Epub 2002 Sep 26.

活化部分凝血活酶时间与未来静脉血栓栓塞风险

Activated partial thromboplastin time and risk of future venous thromboembolism.

作者信息

Zakai Neil A, Ohira Tetsuya, White Richard, Folsom Aaron R, Cushman Mary

机构信息

Department of Medicine, Brown University and Boston University, Providence, RI, USA.

出版信息

Am J Med. 2008 Mar;121(3):231-8. doi: 10.1016/j.amjmed.2007.10.025.

DOI:10.1016/j.amjmed.2007.10.025
PMID:18328308
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2295205/
Abstract

BACKGROUND

Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant tendency.

METHODS

In the Atherosclerosis Risk in Communities study, we studied the 13-year risk of venous thromboembolism in relation to baseline activated partial thromboplastin time in 13,880 individuals. We also studied 258 venous thromboembolism cases and 589 matched controls with measurements of additional coagulation factors.

RESULTS

After adjustment for demographics and procoagulant factors reflected in the activated partial thromboplastin time (fibrinogen, factors VIII, IX, and XI, and von Willebrand factor), participants in the lowest 2 quartiles of activated partial thromboplastin time compared with the fourth quartile had 2.4-fold (95% confidence interval [CI], 1.4-4.2) and 1.9-fold (95% CI, 1.1-3.2) higher risks of venous thromboembolism. The risk associated with activated partial thromboplastin times below the median was higher for idiopathic (odds ratio 5.5; 95% CI, 2.0-15.5) than secondary venous thromboembolism (odds ratio 1.74; 95% CI, 0.88-3.43). Subjects with both activated partial thromboplastin times below the median and factor V Leiden were 12.6-fold (95% CI, 5.7-28.0) more likely to develop venous thromboembolism compared with those with neither risk factor (P interaction<.01). A lower activated partial thromboplastin time also added to the thrombosis risk associated with obesity and elevated D-dimer.

CONCLUSION

A single determination of the activated partial thromboplastin time below the median increased the risk of future venous thromboembolism. Findings were independent of coagulation factor levels, and a low activated partial thromboplastin time added to the risk associated with other risk factors.

摘要

背景

活化部分凝血活酶时间降低与某些凝血因子水平升高相关,可能代表促凝倾向。

方法

在社区动脉粥样硬化风险研究中,我们研究了13880名个体的基线活化部分凝血活酶时间与13年静脉血栓栓塞风险之间的关系。我们还研究了258例静脉血栓栓塞病例和589例匹配对照,并测量了其他凝血因子。

结果

在对人口统计学和活化部分凝血活酶时间所反映的促凝因子(纤维蛋白原、因子VIII、IX和XI以及血管性血友病因子)进行调整后,活化部分凝血活酶时间处于最低两个四分位数的参与者与第四四分位数相比,静脉血栓栓塞风险分别高2.4倍(95%置信区间[CI],1.4 - 4.2)和1.9倍(95%CI,1.1 - 3.2)。活化部分凝血活酶时间低于中位数时,特发性静脉血栓栓塞(比值比5.5;95%CI,2.0 - 15.5)的风险高于继发性静脉血栓栓塞(比值比1.74;95%CI,0.88 - 3.43)。活化部分凝血活酶时间低于中位数且携带因子V莱顿突变的受试者与无这两种危险因素的受试者相比,发生静脉血栓栓塞的可能性高12.6倍(95%CI,5.7 - 28.0)(P交互作用<.01)。较低的活化部分凝血活酶时间也增加了与肥胖和D - 二聚体升高相关的血栓形成风险。

结论

单次测定活化部分凝血活酶时间低于中位数会增加未来静脉血栓栓塞的风险。研究结果与凝血因子水平无关,且低活化部分凝血活酶时间会增加与其他危险因素相关的风险。